Nothing Special   »   [go: up one dir, main page]

JOP20120083B1 - توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns - Google Patents

توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Info

Publication number
JOP20120083B1
JOP20120083B1 JOP/2012/0083A JOP20120083A JOP20120083B1 JO P20120083 B1 JOP20120083 B1 JO P20120083B1 JO P20120083 A JOP20120083 A JO P20120083A JO P20120083 B1 JOP20120083 B1 JO P20120083B1
Authority
JO
Jordan
Prior art keywords
drug
salt
reuptake inhibitor
antidepressant
brexpiprazole
Prior art date
Application number
JOP/2012/0083A
Other languages
English (en)
Inventor
Maeda Kenji
Hirose Tsuyoshi
Kikuchi Tetsuro
Toda Masafumi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46045045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20120083(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of JOP20120083B1 publication Critical patent/JOP20120083B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)

Abstract

يتعلق الاختراع الحالي بدواء له نطاق علاجي أوسع، ويتسبب في آثار جانبية أقل ويكون أقوى من حيث التحمل والأمان، مقارنة بالعوامل المضادة للذهان النمطية المعروفة والعوامل المضادة للذهان غير النمطية. يتعلق الاختراع الحالي بدواء يشتمل على (1) مركب يتمثل في 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one او ملح منه، و (2) عقار واحد على الأقل يتم اختياره من المجموعة المؤلفة من مثبت الحالة المزاجية، مثبط إعادة امتصاص السيروتونين، مثبط إعادة امتصاص النورأبينفرين، مثبط إعادة امتصاص السيروتونين والنورأبينفرين، مضادة للاكتئاب ثلاثي الحلقة، مضاد للاكتئاب رباعي الحلقة، وعقاد مضاد للذهان وعقار مضاد لـ ADHD، في توليفة.andnbsp;
JOP/2012/0083A 2011-04-05 2012-04-03 توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns JOP20120083B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161471911P 2011-04-05 2011-04-05
US201161580540P 2011-12-27 2011-12-27

Publications (1)

Publication Number Publication Date
JOP20120083B1 true JOP20120083B1 (ar) 2021-08-17

Family

ID=46045045

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2012/0083A JOP20120083B1 (ar) 2011-04-05 2012-04-03 توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
JOP/2021/0035A JOP20210035A1 (ar) 2011-04-05 2021-02-25 توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2021/0035A JOP20210035A1 (ar) 2011-04-05 2021-02-25 توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns

Country Status (31)

Country Link
US (6) US20140120185A1 (ar)
EP (4) EP3299018A1 (ar)
JP (2) JP5992924B2 (ar)
KR (1) KR101890450B1 (ar)
CN (2) CN108042808B (ar)
AR (1) AR085840A1 (ar)
AU (1) AU2012240864B2 (ar)
BR (1) BR112013025420B1 (ar)
CA (1) CA2832157C (ar)
CO (1) CO6801769A2 (ar)
CY (1) CY1120567T1 (ar)
DK (1) DK2694043T3 (ar)
EA (1) EA035837B1 (ar)
ES (1) ES2654851T3 (ar)
HK (1) HK1246159A1 (ar)
HR (1) HRP20180098T1 (ar)
HU (1) HUE035542T2 (ar)
IL (1) IL228669B (ar)
JO (2) JOP20120083B1 (ar)
LT (1) LT2694043T (ar)
MX (2) MX370670B (ar)
MY (1) MY166936A (ar)
NZ (1) NZ615591A (ar)
PL (1) PL2694043T3 (ar)
PT (1) PT2694043T (ar)
RS (1) RS56802B1 (ar)
SG (2) SG10201602326RA (ar)
SI (1) SI2694043T1 (ar)
TW (1) TWI636784B (ar)
WO (1) WO2012137971A1 (ar)
ZA (1) ZA201306981B (ar)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3753B1 (ar) * 2011-10-14 2021-01-31 Otsuka Pharma Co Ltd قرص يتألف من 7-[4-(4-بينزو[بي]ثيوفين-4-ايل-ببرازين-1-1ايل)بوتكسيل]-1اتش-كوينولين-2-وان أو ملح منه
AR088372A1 (es) * 2011-10-19 2014-05-28 Otsuka Pharma Co Ltd Solucion para administracion oral
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β－環糊精之藥物製劑
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JOP20210047A1 (ar) * 2012-10-25 2017-06-16 Otsuka Pharma Co Ltd عامل وقائي و/أو علاجي للأعراض السلوكية والنفسية المصحوبة بمرض تنكسي عصبي أو الأعراض الإندفاعية المصحوبة بمرض ذهني، يحتوي على بريكسبيرازول أو ملحه
WO2014144663A1 (en) * 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
AR100153A1 (es) 2014-04-22 2016-09-14 Otsuka Pharma Co Ltd Medicamento
WO2015188092A1 (en) * 2014-06-06 2015-12-10 Rhodes Pharmaceuticals, L.P. Methods for treating attention deficit hyperactivity disorder with methylphenidate
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
AU2017240259A1 (en) 2016-04-01 2018-10-18 Upmc Regulatory device and associated method
EP3500247B1 (en) 2016-08-16 2020-05-27 H e x a l Aktiengesellschaft Immediate release tablet of a benzothiophene compound
EP3500249A1 (en) 2016-08-16 2019-06-26 Hexal Aktiengesellschaft Pharmaceutical compositions of a benzothiophene compound
EP3532064B1 (en) * 2016-10-28 2020-07-29 H. Lundbeck A/S Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3501506B1 (en) * 2017-12-19 2019-10-09 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical tablet composition comprising brexpiprazole
JP6831354B2 (ja) * 2018-08-16 2021-02-17 株式会社Ｄｎｐファインケミカル 接着性組成物からなる錠剤、その製造方法、及び該錠剤を用いた部材又は部品の製造方法
JP2019183095A (ja) * 2018-08-16 2019-10-24 株式会社Ｄｎｐファインケミカル 接着性粉体、接着性錠剤の製造方法、接着性錠剤、並びに該接着性粉体及び錠剤を用いた部材又は部品の製造方法
US11130757B2 (en) * 2018-10-24 2021-09-28 Effector Therapeutics Inc. Crystalline forms of MNK inhibitors
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN114206349A (zh) 2019-04-17 2022-03-18 指南针探路者有限公司 治疗神经认知障碍、慢性疼痛及减轻炎症的方法
JPWO2021029020A1 (ar) * 2019-08-13 2021-02-18
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
CN113322299A (zh) * 2021-05-28 2021-08-31 南昌大学 一种抑郁症和药物成瘾疾病的药物靶点识别方法
US20240009181A1 (en) * 2022-07-08 2024-01-11 Jason Eric Schiffman Method for the treatment and prophylaxis of substance-related and/or addictive disorders including substance/medication-induced depressive disorders, bipolar and related disorders, and anxiety disorders and compositions useful for the same
FR3142667A1 (fr) * 2022-12-01 2024-06-07 Capsum Composition solide non pulvérulente comprenant au moins 8% en poids d’agent(s) désintégrant
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
CA2451914A1 (en) * 2001-08-08 2003-02-20 John-Michael Sauer Combination therapy for the treatment of neurological disorders
CN1989968B (zh) * 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
JP2008504295A (ja) * 2004-06-25 2008-02-14 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 注意欠陥多動性障害及び高フェニルアラニン血症の治療のための方法及び組成物
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
TWI320783B (en) 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4540700B2 (ja) * 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
ES2354319T3 (es) * 2006-10-27 2011-03-14 Janssen Pharmaceutica, N.V. Procedimientos para el tratamiento de trastornos de comportamiento disruptivo.
JP2008189616A (ja) * 2007-02-07 2008-08-21 Mitsubishi Tanabe Pharma Corp 注意欠陥多動性障害の治療薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物

Also Published As

Publication number Publication date
PT2694043T (pt) 2018-01-16
TWI636784B (zh) 2018-10-01
JP2017031155A (ja) 2017-02-09
EP3626243A1 (en) 2020-03-25
SI2694043T1 (en) 2018-03-30
JOP20210035A1 (ar) 2023-01-30
US20220000861A1 (en) 2022-01-06
CN108042808A (zh) 2018-05-18
MX370670B (es) 2019-12-19
KR101890450B1 (ko) 2018-08-21
EP4023223A1 (en) 2022-07-06
PL2694043T3 (pl) 2018-04-30
TW201311242A (zh) 2013-03-16
CN103547260B (zh) 2019-08-13
MX2019015237A (es) 2020-02-13
AR085840A1 (es) 2013-10-30
LT2694043T (lt) 2018-02-12
NZ615591A (en) 2016-02-26
IL228669A0 (en) 2013-12-31
WO2012137971A1 (en) 2012-10-11
EA035837B1 (ru) 2020-08-19
BR112013025420A2 (pt) 2016-12-27
CO6801769A2 (es) 2013-11-29
EP2694043B1 (en) 2017-11-01
CY1120567T1 (el) 2019-07-10
RS56802B1 (sr) 2018-04-30
US20170100395A1 (en) 2017-04-13
EP3299018A1 (en) 2018-03-28
HRP20180098T1 (hr) 2018-03-23
MY166936A (en) 2018-07-25
SG10201602326RA (en) 2016-04-28
CN108042808B (zh) 2021-02-09
ES2654851T3 (es) 2018-02-15
KR20140021648A (ko) 2014-02-20
AU2012240864B2 (en) 2017-02-02
CN103547260A (zh) 2014-01-29
BR112013025420B1 (pt) 2021-10-13
JP2014510023A (ja) 2014-04-24
EA201391450A1 (ru) 2014-03-31
SG193468A1 (en) 2013-10-30
US20180325894A1 (en) 2018-11-15
JP5992924B2 (ja) 2016-09-14
MX2013010796A (es) 2013-12-06
EP2694043A1 (en) 2014-02-12
US20240156811A1 (en) 2024-05-16
HK1246159A1 (zh) 2018-09-07
US20140120185A1 (en) 2014-05-01
IL228669B (en) 2020-04-30
DK2694043T3 (en) 2018-01-15
HUE035542T2 (hu) 2018-05-02
ZA201306981B (en) 2014-05-28
CA2832157C (en) 2023-06-27
CA2832157A1 (en) 2012-10-11
AU2012240864A1 (en) 2013-11-07
US20180042923A1 (en) 2018-02-15

Similar Documents

Publication Publication Date Title
JOP20210035A1 (ar) توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns
EA201171493A1 (ru) МОТИВЫ ХИМИЧЕСКИХ МОДИФИКАЦИЙ ДЛЯ ИНГИБИТОРОВ И МИМЕТИКОВ мкРНК
CO6501189A2 (es) Derivados de oxazina y su uso en el tratamiento de los trastornos neurológicos
DOP2013000192A (es) Compuestos y composiciones como inhibidores de la trk
JO3421B1 (ar) طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
IN2014DN09805A (ar)
MX2015005174A (es) Agente profilactico y/o terapeutico para sintomas conductuales y psicologicos asociados con la enfermedad neurodegenerativa o sintomas impulsivos asociados con enfermedad mental que contiene brexpiprazol o sales del mismo.
EA201790267A1 (ru) Новые модуляторы киназ
IN2014DN09804A (ar)
EA201491933A1 (ru) Дигидрат соединения бензотиофена или его соли и способ его получения
MX2014010560A (es) Composiciones farmaceuticas que comprenden metformina y un inhibidor de dpp-4 o un inhibidor de sglt-2.
EA201201192A1 (ru) Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
SG195106A1 (en) Trpv4 antagonists
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
EA201490103A1 (ru) Гидроксиметиларилзамещенные пирролотриазины в качестве ингибиторов alk1
EA201201201A1 (ru) Новые ингибиторы rock
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201171172A1 (ru) Применение в терапии производных хиназолиндиона
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.
MY157192A (en) Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
EP2416795A4 (en) COGNITIVE DECLINE INHIBITORS
MD4538C1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
MX2012002580A (es) Compuesto antibacteriano novedoso de hidroxifenilo.
MX2011012596A (es) Metodos para incrementar os efectos de un inhibidor selectivo de la recaptacion de serotonina en los mamiferos.
MX2010004313A (es) Compuestos para inhibir la actividad de quinesina de la proteina de quinesina del huso.